Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids.
Using a series of tumorigenic and non-tumorigenic somatic cell hybrids that resulted from the fusion of the human osteosarcoma cell line OHS50-P16T (P16T) with the HeLa cell line D98OR, we investigated the role that genetic mutations, including alterations of oncogenes, tumor suppressor genes, and chromosomes, play in P16T tumorigenicity. Analysis of a previously identified oncogene mutation, c-myc amplification, in the P16T cell line demonstrated that both the tumorigenic and non-tumorigenic hybrids contained the amplified c-myc gene. Analysis of previously identified P16T tumor suppressor gene alterations, p53 mutation, and loss of RB1 expression demonstrated that the mutated p53 gene was selectively maintained in both the non-tumorigenic and tumorigenic hybrids, whereas loss of RB1 expression was not maintained in either the non-tumorigenic or tumorigenic hybrids. Chromosomes 11, 13, 17, and 22 were analyzed for loss of heterozygosity (LOH) to characterize the status of these previously described chromosomal alterations in the tumorigenic and non-tumorigenic hybrids. Loss of HeLa D98OR chromosome 22, with maintenance of P16T chromosome 22, was observed in the tumorigenic hybrids, a result confirmed by LOH analysis, which demonstrated the specific loss of HeLa chromosome 22 genetic material in the tumorigenic segregants. Together, these results demonstrated that amplified c-myc, mutant p53, and RB1 genes seem to be important in osteosarcoma tumorigenicity and that an additional altered gene or genes on chromosome 22 may play a key role in osteosarcoma tumorigenicity.
Isfort
R J
RJ
Human Safety Department, The Proctor & Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio, USA.
Cody
D B
DB
Lovell
G J
GJ
Gioeli
D
D
Weissman
B E
BE
Doersen
C J
CJ
D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002869:Chromosome Aberrations / Q000235:genetics*; D002877:Chromosomes, Human / Q000235:genetics; D005784:Gene Amplification; D016161:Genes, Retinoblastoma / Q000235:genetics; D016147:Genes, Tumor Suppressor / Q000235:genetics*; D016762:Genes, fos / Q000235:genetics; D016259:Genes, myc / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D006822:Hybrid Cells / Q000378:metabolism* / Q000473:pathology; D007621:Karyotyping; D019656:Loss of Heterozygosity; D009154:Mutation; D009857:Oncogenes / Q000235:genetics*; D012516:Osteosarcoma / Q000235:genetics*; D010641:Phenotype; D014407:Tumor Cells, Cultured
D005819:Genetic Markers